Short answer
CG Oncology, Inc. (CGON) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). CG Oncology announced financial results for the quarter ended June 30, 2026.
CG Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CG Oncology announced financial results for the quarter ended June 30, 2026
- Detailed results are provided in Exhibit 99.1, the accompanying earnings press release
- Results furnished under Regulation FD, limiting direct Section 18 liability and automatic incorporation into other filings
Item 8.01 · Other Events
- $500.0M increase in shares available under CG Oncology’s Jefferies at-the-market offering
- Cumulative shares registered and sold under the agreement now approximately $1.05B
- Expanded equity capacity supports funding flexibility but creates potential shareholder dilution
- Cooley LLP validity opinion attached as Exhibit 5.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $79.1M, or $0.90 per share, versus $41.4M and $0.54 year over year
- R&D expense rose to $54.7M from $31.3M, reflecting increased clinical-trial, CMC, and headcount investment
- Cash, equivalents, and marketable securities totaled $1.0B, with funding projected through 2029
- PIVOT-006 Phase 3 topline data anticipated near-term, creating a major clinical catalyst in intermediate-risk NMIBC
- BLA submission for high-risk BCG-unresponsive NMIBC targeted for 4Q 2026, advancing potential commercialization timing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CG Oncology, Inc. 8-K filings
Get the next CGON 8-K as it lands
Follow CGON for push alerts, or ask the research agent what this filing means.